The US Food and Drug Administration has approved Pfizer’s rapid-acting nasal spray for the treatment of migraine.
Pfizer said it expects the drug, sold under the name Zavzpret, to be available in pharmacies in July 2023. “The FDA’s approval of Zavzpret marks a significant breakthrough for people with migraines who need pain relief and prefer alternatives to oral medications,” Pfizer Chief Commercial Officer Angela Hwang said in a statement. A phase 3 study of this drug found that it relieves pain in some migraine sufferers in as little as 15 minutes.
At Focus. Technologies has its own Telegram channel. Subscribe to not miss the latest and exciting news from the world of science!
“As a fast-absorbing nasal spray, Zavzpret offers an alternative treatment option for people who need pain relief but cannot take oral medications due to nausea or vomiting,” Kathleen Mullin, assistant medical director of the Institute of Neurology and Headache, told Pfizer. New England.
The treatment for the condition, which is usually treated with oral medication, was double-blind tested on a sample of 1,405 people, half of whom took a single dose of spray and the rest a placebo.
The spray was found to significantly reduce pain when assessed two hours after the onset of a migraine, which, in addition to severe headache, may be accompanied by nausea and sensitivity to light or noise.
Pfizer bought Zavzpret, also known as Zavegepant, last year for $10 billion from Biohaven, along with other migraine drugs.
In the United States alone, according to official statistics, about 39 million Americans suffer from headaches. This spray, which could become available worldwide, could help hundreds of millions of people quickly deal with annoying and distracting headaches.
Previously, Focus wrote about how to get rid of migraines. It turned out that sugar levels are directly related to headaches.
